Sysafe Medicine

SySafe Medicine is a clinical-stage biotechnology company based in Suzhou, China, focused on the development of mRNA therapeutics and vaccines. The company utilizes a proprietary lipid nanoparticle (LNP) delivery platform and circular RNA (circRNA) technology to create treatments for infectious diseases, oncology, and rare genetic disorders. Its lead candidate, SYS-6002, is an mRNA vaccine targeting COVID-19, while other pipeline programs include a shingles vaccine and various cancer immunotherapies. SySafe is dedicated to advancing the field of RNA medicine through optimized delivery and enhanced molecular stability. The company has secured significant venture capital funding to support its clinical trials and manufacturing scale-up.